COVID toes: where do we stand with the current evidence?

dc.creatorBaeck, Marie
dc.creatorHerman, Anne
dc.date.accessioned2020-10-22T19:55:35Z
dc.date.available2020-10-22T19:55:35Z
dc.date.created2020
dc.description.abstractBackground: Numerous of cases of chilblains have been observed, mainly in young subjects with no or mild symptoms compatible with COVID-19. The pathophysiology of these lesions is still widely debated and an association with SARS-CoV-2 infection remains unconfirmed. Objectives: This paper focus on the unresolved issues about these COVID toes and in particular whether or not they are associated with COVID-19. Arguments: - The temporal link between the outbreak of chilblains and the COVID-19 pandemic is a first suggests a link between the two events. Journal Pre-proof 3 - Positive anti-SARS-CoV/SARS-CoV-2 immunostaining on skin biopsy of chilblains seem to confirm the presence of the virus in the lesions, but lack specificity and must be interpreted with caution. - Conversely, RT-PCR and anti-SARS-CoV-2 serology were negative in the majority of patients with chilblains. Therefore, SARS-CoV-2 infection can be excluded, with relative certainty, even after accounting for possible lower immunization in mild/asymptomatic patients and for some differences in sensitivity/specificity between the tests used. - Some authors hypothesize that chilblains could be the cutaneous expression of a strong type I interferon (IFN-I) response. High production of IFN-I is suggested to be associated with early viral control and may suppress antibody response. However, the absence of other cutaneous or extracutaneous symptoms as observed in other interferonopathies raises unanswered questions. - To date, a direct link between chilblains and COVID-19 still seems impossible to confirm. A more indirect association due to lifestyle changes induced by lockdown is a possible explanation. Improvement of chilblains when protective measures were adopted and after lifting of lockdown, support this hypothesis. Conclusion: Conflicting current evidence highlights the need for systematic and repeated testing of larger numbers of patients and the need for valid follow-up data that take into consideration epidemic curves and evolution of lockdown measures.spa
dc.format.extent11 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1016/j.ijid.2020.10.021spa
dc.identifier.issn1201-9712spa
dc.identifier.otherhttps://doi.org/10.1016/j.ijid.2020.10.021spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/14779
dc.language.isoengspa
dc.publisherInternational Journal of Infectious Diseasesspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.localAbierto (Texto Completo)spa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subjectSARS-CoV-2spa
dc.subjectChilblainsspa
dc.subjectCOVID toesspa
dc.subjectAcral lesionsspa
dc.subjectSerology testsspa
dc.subjectRT-PCRspa
dc.subjectPandemicspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleCOVID toes: where do we stand with the current evidence?spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción: